Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Passive immunisation with long-acting monoclonal antibodies (nirsevimab) targeting the two antigenic subgroups A and B of respiratory syncytial virus (RSV) was authorised by the European Medicines Agency for use in the European Union on 31 October 2022.
Clesrovimab for Prevention of RSV Disease in Healthy Infants
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein.
WHO EPI-WIN Webinar: Respiratory Syncytial Virus (RSV) genomic surveillance – how & why
Each year, RSV causes an estimated 3.6 million RSV-associated hospitalisations and approximately 100.000 RSV-attributable deaths in children under 5 years of age worldwide .
Influenza-Associated Acute Necrotizing Encephalopathy in US Children
The high morbidity and mortality emphasize the need for prevention, early recognition, intensive treatment, and standardized management protocols.
Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
Annual vaccination with LAIV4 or IIV4 remains the best way to protect children against influenza infection.
WHO position paper on immunization to protect infants against respiratory syncytial virus disease
Recommendations on the use of maternal respiratory syncytial virus (RSV) vaccines and long-acting RSV monoclonal antibodies (mAbs) to prevent severe RSV disease in infants were issued by the WHO Strategic Advisory Group of Experts (SAGE)
Strategies to increase influenza vaccination coverage in the Italian pediatric population: a literature review and expert opinion
Vaccination rates in Italian children must be substantially increased to control the transmission of seasonal influenza and mitigate the associated socio-economic burden.
What COVID-19 taught us about protecting kids in future pandemics
Five years after the World Health Organization declared COVID-19 a global pandemic, infectious disease experts continue to draw on its lessons for future disasters.